The agreement signed today strengthens the Company's finances to ensure its ongoing operations.

The loan is taken out at an interest rate of 4% per quarter on the granted loan. The lenders will be given the opportunity to use all or part of the disbursed loan, including accrued and unpaid interest, as an offset in the event of a new issue.

“I appreciate the support from the board to extend our operations into 2023 which gives us enough time to raise long-term capital as well as continue our revenue-focused strategy."-says Mohan Frick, CEO of Scandinavian ChemoTech

"We are in a very exciting period in the company's life with plenty of milestones met and we look forward tocontinue our commercialisation process." - says Lars Hedbys, Chairman of the Board of Scandinavian ChemoTech

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 16-08-2022 08:15 CET.

Ämnen i artikeln


Scandinavian ChemoTech B

Senast

2,15

1 dag %

4,88%

1 dag

1 mån

1 år

Marknadsöversikt

OMX Stockholm 30

1 DAG %

−0,11%

Senast

2 446,55

1 mån
Loading market data...
Senaste aktieanalyserna på Placera
Kollage Analys Ny
Privatekonomi med Placeras expert
Karolina Palutko Macéus
Karolina Palutko Macéus skriver om allt som har med privatekonomi att göra och hur du kan få mer pengar i plånboken.
Affärsvärlden
AFV
Är du kund hos Avanza? Just nu kan du få en unik rabatt på Affärsvärlden. Afv har 28 år i rad utsetts till Sveriges bästa affärsmagasin i en undersökning med börs-VD:ar, finanschefer, IR-chefer och aktieproffs.
Annons
Introduce
för börsens små- och medelstora företag.
Annons
Investtech
Här hittar du våra artiklar om teknisk analys i samarbete med Investtech.